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The extra virgin olive oil (EVOO) dihydroxy-phenol oleacein is a natural inhibitor of multiple metabolic and 
epigenetic enzymes capable of suppressing the functional traits of cancer stem cells (CSC). Here, we used a 
natural product-inspired drug discovery approach to identify new compounds that phenotypically mimic the 
anti-CSC activity of oleacein. We coupled 3D quantitative structure-activity relationship-based virtual profiling 
with phenotypic analysis using 3D tumorsphere formation as a gold standard for assessing the presence of CSC. 
Among the top 20 computationally-predicted oleacein mimetics, four fulfilled the phenotypic endpoint of 
specifically suppressing the tumorsphere-initiating capacity of CSC, in the absence of significant cytotoxicity 
against differentiated cancer cells growing in 2D cultures in the same low micromolar concentration range. Of 
these, 3,4-dihydrophenetyl butyrate –a lipophilic ester conjugate of the hydroxytyrosol moiety of oleacein– and 
(E)-N-allyl-2-((5-nitrofuran-2-yl)methylene)hydrazinecarbothioamide) –an inhibitor of Trypanosoma cruzi 
triosephosphate isomerase– were also highly effective at significantly reducing the proportion of aldehyde 
dehydrogenase (ALDH)-positive CSC-like proliferating cells. Preservation of the mTOR/DNMT binding mode of 
oleacein was dispensable for suppression of the ALDH+-CSC functional phenotype in hydroxytyrosol-unrelated  
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mimetics. The anti-CSC chemistry of complex EVOO phenols such as oleacein can be phenocopied through the 




Extra virgin olive oil (EVOO) is a unique functional 
food with a major contribution to the health-promoting 
effects of the so-called Mediterranean diet. EVOO 
contains a group of complex phenol-conjugated 
compounds named oleosidic secoiridoids or oleosides 
that exert nutritional and beneficial effects on major 
aging-driven diseases including cancer [1–10]. Using a 
holistic approach for phenotypic drug discovery coupled 
with mechanism-of-action functional profiling and 
target deconvolution, we recently identified the 
dihydroxy-phenol oleacein (the dialdehydic form of 
decarboxymethyl elenolic acid linked to 
hydroxytyrosol) [11–17] as a metabolo-epigenetic 
inhibitor of the mammalian target of rapamycin 
(mTOR) kinase and DNA methyltransferases (DNMTs). 
Oleacein was found to specifically and potently 
suppressing the functional traits of tumor-initiating 
cancer stem cells (CSC) in genetically diverse types of 
cancer cell populations [18].  
 
The anti-CSC effects of oleacein are most likely related 
to its chemical structure, largely due to the presence of 
two hydroxyl groups in the hydroxytyrosol moiety [9, 
19–21]. Therefore, one could envision that its scaffold 
might be used as a chemical prototype to facilitate 
selection and advancement of new anti-CSC hits via 
cell-based phenotypic screenings. However, a recent 
delineation of the high-level functions of oleacein in 
terms of biomolecular interactions, signaling pathways, 
and protein-protein interaction networks revealed that 
the so-called oleacein target landscape likely involved 
more than 700 proteins rather than solely mTOR and 
DNMTs [22]. Thus, although the ability of oleacein to 
operate as a multi-faceted regulator of numerous 
metabolic processes and chromatin-modifying 
enzymatic activities might open new horizons for CSC-
targeted therapy based on the molecular bridge that 
connects metabolism and epigenetics with the aberrant 
state of stemness in cancer tissues [23–28], a 
biomimicry design process of oleacein mimetics 
remains a highly challenging task.  
 
Here, we used a natural-product-inspired drug discovery 
approach to identify new small molecules capable of 
phenotypically mimicking the anti-CSC actions of 
oleacein. Using the structure of oleacein as a “seed”, we 
coupled 3D quantitative structure-activity relationship 
(3D-QSAR)-based virtual profiling (VP) with 
laboratory-based phenotypic testing using tumorsphere-
formation potential as a gold standard for evaluating the 
presence of CSC (Figure 1). We provide evidence that 
oleacein can be phenocopied through the use of 
mimetics with anti-CSC activity, which might guide the 
design of synthetically tractable small molecules 
capable of phenotypically imitating the anti-CSC 




Computer-assisted discovery of oleacein mimetics 
 
When a 2D similarity, ligand-based VP program was 
executed over the Chembl(v19) database using the 
Tanimoto coefficient and 2D (Morgan/circular) 
fingerprints, only the closely related secoiridoid 
molecule oleocanthal (CHEMBL2172394) was 
identified. The execution of a comparative molecular 
similarity indices analysis (CoMSIA)-based 3D VP 
program, however, identified several compounds with 
physico-chemical similarity scores greater than 0.75 
(Figure 1). Taking advantage of the previously 
described binding modes of oleacein to mTOR and 
DNMT [18], we ran rigid-docking calculations to 
characterize the binding modes of the top 20 oleacein 
mimetics (Supplementary Figure 1), both at the 
crystallographic sites and at additional cavities 
occurring within the whole protein structures of mTOR 
and DNMT (Supplementary Tables 1–3). Table 1 
summarizes the computationally-predicted oleacein 
mimetics ranked according to reweighted energies 
based on short molecular dynamics (MD) simulations 
followed by molecular mechanics with generalized 
Born and surface area solvation (MM/GBSA) 
calculations, for both the crystallographic and the best 
mTOR/DNMT cavities for each of the selected oleacein 
mimetics (Supplementary Tables 4 and 5).  
 
Binding modes of oleacein mimetics to mTOR and 
DNMT 
 
The binding mode of oleacein to mTOR was predicted 
to share key amino acid residues with the binding 
modes of second-generation ATP-competitive 
TORKinhibs and, consequently, partially mimicked the 
binding behavior of PP242 and Torin 2 to the ATP-
binding catalytic pocket [18]. But, the presence of more 
aromatic rings in the oleacein molecule resulted in a 
slightly different binding strength from that of PP242 
and Torin 2. Similarly, the presence of aromatic rings 
notably influenced the binding of the selected oleacein 
mimetics to mTOR (Figure 2). In fact, we predicted 
three different binding modes, one of them involving 5 
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oleacein mimetics that apparently shared the originally 
described binding mode of parental oleacein; and 
another two models encompassing 13 compounds and 2 
compounds showing a binding mode closely resembling 
that of TORKinhibs (Figure 2). Rigid docking 
calculations originally predicted that π-π stacking would 
occur between the aromatic ring of oleacein and the 
Trp2239 residue (or Tyr2225 upon conformational 
changes of either oleacein or the mTOR catalytic pocket 
itself) in the catalytic site of mTOR. MD simulations 
confirmed the main occurrence of π-π stacking with 
Trp2239 (and a more fluctuating interaction with 
Tyr2225), as well as a significant number of additional 
residues providing key electrostatic interactions [18]. In 
the case of oleacein mimetics, it was evident that 




Figure 1. Computer-assisted discovery of oleacein 
biomimetics with anti-CSC activity. Schematic illustration of 
the computational framework coupled to laboratory-based 
phenotypic testing. The values in parentheses are similarity 
scores calculated with respect to parental oleacein.  
the stabilization of their respective complexes with 
mTOR (Supplementary Table 6).  
 
The binding mode of oleacein to DNMT was predicted 
to closely resemble that of DNMT inhibitors such as 5-
azacytidine, SGI-110, and curcumin [18]. In the case of 
oleacein mimetics, we were able to predict two different 
binding modes (Figure 3): one of them shared the 
oleacein pattern of spatial orientation and included 17 
compounds and another one involved only 3 molecules 
(Figure 3). Rigid docking calculations and MD 
simulations predicted that the main residues involved in 
the stabilization of the oleacein-DNMT complex were 
Ser1446, Pro1125, Asp1143, Phe1145, Gly1150, 
Leu1151, Asn1158, Val1580, and Gly1223, along with 
a significant number of additional residues providing 
key electrostatic interactions. In the case of oleacein 
mimetics, Phe1145, Trp1170, Pro1224, and Pro1225 
were predicted as the main catalytic residues 
(Supplementary Table 7).  
 
Oleacein mimetics specifically suppress CSC-driven 
mammosphere formation 
 
To explicitly test the oleacein mimetics on CSC, we 
measured their effect on in vitro tumorsphere formation 
in low-density non-adherent serum-free medium 
supplemented with growth factors [29–35], considered 
one of the gold standards for evaluating CSC self-
renewal activity. As a source of CSC, we used the CSC-
enriched triple-negative breast cancer model MDA-MB-
436, which can form smooth and round tumorspheres 
(mammospheres) in suspension culture [33]. The 
Cell2Sphere™ assay [18, 36, 37] was used to evaluate 
the differential ability of oleacein mimetics to 
specifically suppress the ability of CSC to survive and 
proliferate as floating 3D microtumors without 
promoting nonspecific, cytotoxic effects on the same 
cells grown in 2D adherent, differentiating conditions 
(Figure 4).  
 
Using the focal adhesion kinase inhibitor VS-6063 
(defactinib) [38–40] and the lysine-specific demethylase 
KDM1A inhibitor ORY-1001 (iadademstat) [37, 41] as 
mechanistically distinct anti-CSC compounds and 
selecting a 10 µmol/L cut-off for 2D cytotoxicity (i.e., 
lower than the original IC50 value of oleacein [18 ± 5 
µmol/L] against CSC-driven mammosphere formation), 
4 out of the 14 oleacein mimetics tested specifically 




thioamide), CHEMBL126593 (N-(4-nitrobenzyl)ethe 
nesulfonamide), and CHEMBL1950046 (3,4-dihy 
droxyphenethyl butyrate), while not exerting significant 
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Table 1. MM/GBSA-based binding energy rescoring calculations over MD simulations of computationally-predicted 
oleacein mimetics. 
Candidates ranked by 
MM/GBSA energy  
4JT6 (mTOR) 
MM/GBSA energy 
Crystallographic cavity / 
Best cavity 
Candidates ranked by 
MM/GBSA energy  
4WXX (DNMT) 
MM/GBSA energy 
Crystallographic cavity / 
Best cavity 
oleacein -26.8226 / -36.9331 oleacein -30.567 / -36.5163 
CHEMBL1300434 -38.7014 / -27.361 CHEMBL1632504 -38.2609 / -36.6319 
CHEMBL2143987 -32.4070 / -40.3344 CHEMBL2143987 -36.4821 / -43.6863 
CHEMBL1545778 -30.5493 / -25.0387 CHEMBL2165395 -33.4134 / -25.8227 
CHEMBL126593 -29.2106 / -26.6329 CHEMBL1300434 -33.3421 / -33.9773 
CHEMBL1085246 -27.4436 / -19.6725 CHEMBL267516 -32.8788 / -28.1508 
CHEMBL267516 -27.3710 / -44.6454 CHEMBL1180264 -31.7196 / -32.3981 
CHEMBL45196 -27.2624 / -17.1961 CHEMBL357073 -28.4676 / -27.0541 
CHEMBL1632504 -25.7896 / -24.6272 CHEMBL1440472 -27.5899 / -29.3600 
CHEMBL357073 -25.0102 / -33.5462 CHEMBL1621113 -26.6488 / -29.3269 
CHEMBL1366164 -24.3303 / -17.8085 CHEMBL1890048 -26.0912 / -26.2952 
CHEMBL1642794 -24.1435 / -19.439 CHEMBL126593 -25.7134 / -35.3592 
CHEMBL1621113 -22.9663 / -21.0309 CHEMBL45196 -24.5175 / -32.1555 
CHEMBL1950046 -20.2999 / -31.6794 CHEMBL1950046 -24.3167 / -21.7283 
CHEMBL2165395 -19.8235 / -27.2639 CHEMBL1079062 -24.2025 / -24.4205 
CHEMBL1890048 -19.6392 / -21.2089 CHEMBL1545778 -21.6215 / -22.9832 
CHEMBL2172394 -18.4177 / -34.4392 CHEMBL1085246 -17.8140 / -21.8923 
CHEMBL1180264 -18.2272 / -29.4140 CHEMBL1642794 -16.1264 / -20.6555 
CHEMBL1079062 -17.4413 / -24.7585 CHEMBL1366164 -15.4957 / -19.6201 
CHEMBL1440472 -16.6468 / -21.2853 CHEMBL165714 -12.1247 / -30.3770 
CHEMBL165714 -16.1321 / -21.4634 CHEMBL2172394 -11.8887 / -31.0757 
 
cytotoxic effects against differentiated cancer cells 
growing in 2D in the same low micromolar range 
(Figure 5). CHEMBL1085246 (N-(4-chloro-5-
nitrothiazol-2-yl)hexanamide) exhibited anti-CSC 
activity due to unspecific cytotoxicity against CSC and 
non-CSC cells (Supplementary Figure 2).   
 
Oleacein mimetics target ALDH
+
 breast cancer stem 
cells 
 
Oleacein selectively suppresses functional traits of CSC 
such as the expression of aldehyde dehydrogenase 
(ALDH) [18], a well-recognized marker of tumorigenic 
cell fractions enriched for proliferating, epithelial-like 
CSC capable of self-renewal [31, 32, 35, 42]. We next 
selected the 2 oleacein mimetics with the best CSC-
targeted profile (i.e., anti-CSC activity at low micromolar 
range and lack of cytotoxic activity against differentiated 
cancer cells), namely CHEMBL1950046 (3,4-
dihydroxyphenethyl butyrate; a.k.a. hydroxytyrosol 
butyrate) and CHEMBL1632504 ((E)-N-allyl-2-((5-
nitrofuran-2-yl)methylene)hydrazinecarbothioamide), to 
evaluate their capacity to target epithelial-like CSC cells 
with high levels of ALDH1 (ALDH1
+
). To do this, we 
used the Aldefluor
®
 reagent, which quantifies ALDH 
activity by measuring the conversion of the ALDH 
substrate BODIPY aminoacetaldehyde to the fluorescent 
product BODIPY aminoacetate (Figure 6A). Using 
HER2-overexpressing BT-474 cells as a breast cancer 
model naturally enriched with ALDH1
+
 cells, we detected 
a significant decrease (up to 63% reduction) in the 
number of ALDH1
+
 cells when BT-474 cells were treated 
with a non-cytotoxic concentration (10 µmol/L) of 
CHEMBL1950046 (hydroxytyrosol butyrate). A more 
pronounced effect was seen with CHEMBL1632504 ((E)-
N-allyl-2-((5-nitrofuran-2-yl)methylene)hydrazinecarboth 
ioamide), which significantly decreased the proportion of 
ALDH
+
 cells from 40±2% in untreated BT-474 cells to 
levels as low as 2±1% (96% reduction). To corroborate 
the ability of oleacein mimetics to target ALDH1
+
 
epithelial-like CSC irrespective of the mutational 
landscape of cancer cells, we employed triple-negative 
MDA-MB-436 cells as a second breast cancer model 
naturally enriched with ALDH1
+
 cells. Treatment with 
hydroxytyrosol butyrate decreased the ALDH1
+
 cell 
content of MDA-MB-436 by approximately 40%. 
Remarkably, the large population of ALDH1
+
 cells in 
untreated MDA-MB-436 cultures (42±8%) was 
drastically reduced by 93% (from 42±8% to 3±1%) in the 
presence of (E)-N-allyl-2-((5-nitrofuran-2-yl)meth 
ylene)hydrazinecarbothioamide.  
 
Preservation of the oleacein binding mode is required 
for a dual mTOR/DNMT inhibitory activity but not for 
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their anti-CSC behavior of oleacein mimetics. We 
finally evaluated whether the selected mimetics 
hydroxytyrosol butyrate and (E)-N-allyl-2-((5-
nitrofuran-2-yl)methylene)hydrazinecarbothioamide 
preserved the dual anti-mTOR/DNMTactivity of the 
parental oleacein.  
 
We first employed the FRET-based Z-LYTE™ Kinase 
Assay to test the ability of the selected oleacein 
mimetics to inhibit mTOR activity. Ten concentrations 
of hydroxytyrosol butyrate and (E)-N-allyl-2- 
((5-nitrofuran-2-yl)methylene)hydrazinecarbothioamide 
spanning over five logarithmic decades were selected. 
Figure 6B shows the mTOR activity rate as a function 
of oleacein mimetics concentration. Hydroxytyrosol 
butyrate inhibited mTOR activity with an IC50 of ~39 
μmol/L; (E)-N-allyl-2-((5-nitrofuran-2-yl)methylene) 
hydrazinecarbothioamide was unable to decrease 
mTOR activity even at the maximum concentration 
tested.  
 
We finally carried out a radioisotope-based 
methyltransferase profiling measuring the DNMT3A-




H]) into DNA (DNA 5-[methyl-
3




Figure 2. Binding modes of oleacein mimetics to mTOR. Left panels. Graphical representation of the binding modes of the 
computationally-predicted oleacein mimetics to the catalytic cavity of mTOR. The black, red, and purple arrows indicate the location of the 
aromatic rings in the binding modes #1, #2, and #3, respectively. Right panels. Graphical representation of the binding modes of parental 
oleacein and selected oleacein mimetics with anti-CSC activity (Figure 4, 5) to the catalytic cavity of mTOR.  
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mimetics. The selected oleacein mimetics were tested in 
10-dose IC50 mode with 2-fold serial dilution and 
reactions were carried out at 1 µmol/L SAM. Although 
hydroxytyrosol butyrate decreased DNMT3A activity in 
a dose-dependent manner, concentrations higher than 
150 µmol/L were necessary to reach the IC50 value. (E)-
N-allyl-2-((5-nitrofuran-2-yl)methylene)hydrazinecarbo 
thioamide did not reach the half maximal inhibitory 




The molecular frameworks of natural products can 
provide feasible and innovative templates for medicinal 
chemistry and drug discovery [43]. But, despite the long 
tradition of natural product-inspired discovery of 
synthetic compounds, there has been little effort to 
utilize EVOO biophenols chemotypes as a springboard 
for lead discovery. Here, we carried out such a drug 




Figure 3. Binding modes of oleacein mimetics to DNMT. Left panels. Graphical representation of the binding modes of the 
computationally-predicted oleacein mimetics to the catalytic site of DNMT. The black and red arrows indicate the location of the aromatic 
rings in the binding modes #1 and #2, respectively. Right panels. Graphical representation of the binding modes of parental oleacein and 
selected oleacein mimetics with anti-CSC activity (Figures 4 and 5) to the catalytic cavity of DNMT.  
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Figure 4. Phenotypic screening of the anti-CSC activity of oleacein mimetics (I). Left. Comparative analysis of IC50 values of the 
computationally-predicted oleacein mimetics in 2D monolayer cultures and 3D mammosphere systems. With 10 µmol/L as a cutoff, 4/16 
compounds tested were more potent in 3D than in 2D and were selected as anti-CSC candidates; 1/16 compounds tested was equally potent 
in 3D and in 2D and was designated as cytotoxic. Right. CHEMBL structures of the computationally-predicted oleacein mimetics with anti-CSC 




Figure 5. Phenotypic screening of the anti-CSC activity of oleacein mimetics (II). Top panels. MTT reduction-based measurement of 
cell viability is expressed as percentage uptake (OD570) relative to untreated controls (=100% cell viability). Bottom panels. Representative 
microscope images (×2.5 magnification) of mammospheres formed by MDA-MB-436 cells growing in sphere medium for 6 days in the 
absence or presence of graded concentrations of oleacein mimetics. The number of mammospheres (>100 µm diameter) is expressed as 
means (columns) ± SD (bars). *P < 0.05 and **P < 0.005, statistically significant differences from the untreated (control) group. 
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of phenotypically mimicking the anti-CSC effects of the 
EVOO dihydroxy-phenol oleacein.  
 
We took advantage of modern bioinformatics 
approaches with the aim of identifying physicochemical 
mimetics of the anti-CSC behavior of EVOO-derived 
oleacein. First, the somewhat structurally complex 
framework of the dialdehydic form of decarboxymethyl 
elenolic acid linked to hydroxytyrosol (i.e., oleacein) 
was computationally captured in terms of molecules 
with oleacein-like physico-chemical profiles. Second, 
we in silico compared the binding modes of the top 20 
computationally-predicted oleacein mimetics to the two 
molecular targets originally involved in the capacity of 
oleacein to specifically suppress the functional traits of 
tumor-initiating CSC (i.e., mTOR and DNMT) [14]. 
Third, we phenotypically explored the computationally-
discovered oleacein biomimetics in terms of their anti-
CSC activity. Fourth, we evaluated the structure-
mTOR/DNMT bioactivity relationship of the most 
promising oleacein-mimetic candidates. By doing so, 
four oleacein mimetics, namely N’-[4-nitro-2-
(trifluoromethyl)phenyl]propane-1,3-diamine, (E)-N-
allyl-2-((5-nitrofuran-2-yl)methylene)hydrazinecarboth 
ioamide, N-(4-nitrobenzyl)ethenesulfonamide, and 3,4-
dihydroxyphenethyl butyrate  (a.k.a. hydroxytyrosol 
butyrate), fulfilled the first phenotypic endpoint of the 
selection criteria, which was the specific suppression of 
the 3D mammosphere forming capability of CSC in the 
low micromolar range without highly significant 
cytotoxic effects against differentiated cancer cells 
growing in 2D cultures in the same range of 
concentrations. Moreover, non-cytotoxic concentrations 
of the oleacein mimetics hydroxytyrosol butyrate and 
(E)-N-allyl-2-((5-nitrofuran-2-yl)methylene)hydrazine 
carbothioamide efficiently suppressed the population of 
ALDH1
+
 epithelial-like proliferating CSC [31, 32, 35, 
42], a second phenotypic endpoint of the selection 
criteria for anti-CSC candidates.  
 
The fact that the oleacein mimetics-responsive 




Figure 6. Phenotypic screening of the anti-CSC activity of oleacein mimetics (III). (A) Changes in the number of ALDH+ cells in BT-
474 and MDA-MB-436 populations cultured in the absence or presence of 11.1 µmol/L of CHEMBL1950046 and CHEMBL1632504. The results 
are expressed as percentages means (columns) ± SD (bars). *P < 0.05 and **P < 0.005, statistically significant differences from the untreated 
(control) group. (B) Left. A dose-response inhibition curve of ATP-dependent activity of mTOR kinase was created by plotting FRET signal of 
the Z´-LYTE Kinase assay as the function of CHEMBL1950046 and CHEMBL1632504 concentrations. Right. Dose-response curves of SAM-
dependent methylation activity of DNMT3A were created by plotting radioisotope signals of the HotSpot
SM
 assay as the function of 
CHEMBL1950046 and CHEMBL1632504 concentrations. (C) Molecular scaffolds of oleacein. 
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cell culture conditions along with their capacity to 
specifically and potently suppress (>90%) ALDH1
+
 CSC-
like cellular states irrespective of the mutational landscape 
of the cancer cell population strongly suggested that their 
mechanism of action targets the biological functioning of 
cancer stemness per se.  Hydroxytyrosol butyrate is a 
chemically-modified (alkyl ester) lipophilic version of 
hydroxytyrosol that is more stable than parental 
hydroxytyrosol under biological conditions [44–49]. The 
fact that the inclusion of a short-medium lipophilic chain 
in the hydroxytyrosol molecule sufficed to recapitulate, at 
least in part, both the anti-CSC behavior and the anti-
mTOR/DNMT inhibitory activity of the parental oleacein 
highlights the functional relevance of the dihydro-
xybenzene moiety within the phenolic part of oleacein, a 
scaffold that seems to be a crucial mediator of the 
metabolo-epigenetic modulatory effects of oleacein (e.g., 
COMT, IDH1, LSD1 [18, 22, 50–52]) via formation of 
stacking interactions, coordination with metal ions, and/or 
establishment of hydrophobic and/or hydrogen bond 
interactions through the hydroxyl groups or the aromatic 
ring (Figure 6C). The second oleacein scaffold, which 
comprises the secoiridoid dialdehyde part, might be 
involved in the stabilization of oleacein via hydrophobic 
interactions within the binding pocket of the targeted 
proteins. Accordingly, although hydroxytyrosol butyrate 
preserved the original double occupancy of oleacein 
within the catalytic sites of mTOR and DNMT, the sole 
dihydroxybenzene moiety does not suffice to fully 
preserve the low-micromolar biological activity of 
oleacein against mTOR and DNMT enzymatic activities. 
(E)-N-allyl-2-((5-nitrofuran-2-yl)methylene)hydrazinecar-
bothioamide, originally described as an inhibitor of the 
Trypanosoma cruzi triosephosphate isomerase [53], 
lacked the original binding sites of oleacein to mTOR and 
DNMT, thereby fully losing the original ability of 
oleacein to operate as a dual mTOR/DNMT inhibitor. (E)-
N-allyl-2-((5-nitrofuran-2-yl)methylene)hydrazinecarbo-
thioamide, however, appeared to operate as an optimized 
mimetic of oleacein capable of exhibiting a very 
promising and potent activity against ALDH1-positive 
breast CSC. These findings can be consistent with the 
notion that preservation of the original binding mode of 
oleacein to mTOR and DNMT is an obligatory 
requirement for a dual mTOR/DNMT inhibitory activity 
of hydroxytyrosol-related oleacein mimetics (e.g., 
hydroxytyrosol butyrate) with anti-CSC activity; for 
hydroxytyrosol-unrelated oleacein mimetics (e.g., (E)-N-
allyl-2-((5-nitrofuran-2-yl)methylene)hydrazinecarbothio-
amide), however, the absence of a dual mTOR/DNMT 
inhibitory activity is dispensable for an efficient 
suppression of the ALDH
+
-CSC functional phenotype.  
 
We provide, to the best of our knowledge, the first 
evidence that the pharma-nutritional properties of 
oleacein that elicit its functioning as an anti-CSC 
compound can be phenocopied through the use of 
mimetics that capture its physico-chemical properties. 
Although we acknowledge that further studies are 
needed to validate the ability of oleacein mimetics to 
functionally deplete tumor-initiating CSC-like states in 
vivo and the mechanisms underlying their mode of 
action, it is reasonable to suggest that a biomimicry 
design process might guide the development of 
synthetically tractable small molecules capable of 
phenotypically imitating the anti-CSC chemistry of 
complex EVOO phenolics such as oleacein.   
 
MATERIALS AND METHODS 
 





A mixture of 4-nitrophenylacetic acid (100 mg, 0.552 
mmol) and CDI (94mg, 0.58 mmol) in DMF (1.4 mL) 
was stirred at 50° C for 10 min. The solution was cooled 
to 20° C, N,N-dimethylaminoethylamine (63.6 µL, 0.58 
mmol) was added dropwise and the solution stirred for 
2 h. The solution was poured into water and extracted 
with EtOAc (3×). The combined organic extracts were 
washed with water, brine, dried, and the solvent 
removed under reduced pressure. The residue was 
chromatographed, eluting with a DCM/MeOH 
(1%NH3) yielding N-(N,N-dimethylaminoethyl)-2-4-




5-Nitrofuran-2-carbaldehyde (100 mg, 0.709 mmol), N-
allylhydrazinecarbothioamide (93 mg, 0.709 mmol), p-
TSA (6.74 mg, 0.035 mmol) and toluene (7.0 mL) were 
stirred at room temperature until the aldehyde was not 
present (1.5h). The solid formed (136 mg, 75%) was 





 4-Nitrophenyl)methanamine (100 mg, 0.657 mmol) 
was dissolved in DCM (620 µL, dry) at 0° C with 
stirring under N2 to which a 4-methylmorpholine (145 
µl, 1.314 mmol) was added with stirring. A solution of 
y 2-chloroethanesulfonyl chloride (68.7 µl, 0.657 
mmol)  dissolved in DCM (620 µL, dry) was added at 
0° C with stirring 10 min under N2, after which time the 
reaction mixture was stirred at room temperature 
overnight. The reaction mixture was extracted with 
dilute hydrochloric acid and the organic layers were 
collected, dried (MgSO4), filtered and the solvent 
removed under reduced pressure. The crude product 
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was purified by column chromatography (EtOAc/n-
hexane 1/2). The product was obtained as a white solid 
(11 mg, 7%). 
 
CHEMBL1950046 (3,4-Dihydroxyphenethyl butyrate) 
Lipase P (25 mg) and vinyl butyrate (412 µl, 3.24 
mmol) were added to a solution of 4-(2-
hydroxyethyl)benzene-1,2-diol (25 mg, 0.162 mmol) in  
tBuOMe (Volume: 5792 µl) and the mixture was shaken 
at 40° C for 60 min. The reaction was quenched by 
filtering off enzyme and the filtrate was evaporated in 
vacuo. The resulting residue was dissolved in EtOAc 
and washed with sat. NaHCO3 and brine then dried 
(MgSO4) followed by filtration and evaporation to 
dryness. 32 mg (89%) of compound identified as the 




To a solution of 2-methyl-5-nitroaniline (100 mg, 0.657 
mmol) in DCM (0.04 M), TEA (0.137 ml, 0.986 mmol) 
and2-methoxyacetyl chloride (0.066 µl, 0.723 mmol) 
were added. The reaction mixture was stirred at room 
temperature for 4 h. 103 mg (70%) of compound 




Hexanoyl chloride (38.2 µl, 0.278 mmol) was dissolved 
in THF (0.1 M) and cooled to -78° C then 4-chloro-5-
nitrothiazol-2-amine (50 mg, 0.278 mmol) was added in 
one portion. DIPEA (1.1 eq) was added to the resulting 
slurry at -78° C and the solution was held at this 
temperature for 10 min then allowed to warm to room 
temperature overnight. The solution was diluted with 
EtOAc and washed with sat. NaHCO3, 1M HCl and 
brine then dried (MgSO4) followed by filtration and 
evaporation to dryness. The resulting residue was 
purified by gradient flash column chromatography (10-
60% EtOAc/hexanes or 1-2% MeOH/CH2Cl2) to obtain 





A mixture of  5-chloro-2-nitroaniline (50 mg, 0.290 
mmol) and (S)-N-(2,5-dioxotetrahydrofuran-3-yl)-2,2,2-
trifluoroacetamide (61.2 mg, 0.290 mmol) was 
irradiated for 60 minutes in a microwave (130° C, 200 
psi, 200W). The residue was purified by reversed-phase 
flash chromatography, yielding 14 mg (12%) of 
compound identified as the title compound. 
 
CHEMBL357073 (6-[(4-nitrophenyl)formamido]hexa 
noic acid), CHEMBL1545778 ([2-(methylcarbamoyla 
mino)-2-oxo-ethyl] (E)-3-(3-bromophenyl)prop-2-
enoate), CHEMBL1366164 (ethyl 2-[(2-methyl-5-nitro-
phenyl)amino]-2-oxoacetate), and CHEMBL1642794 
([2-(tert-butylamino)-2-oxo-ethyl] 4-nitrobenzoate) 
were purchased from Enamine (EN300-302808, Z1864 
6098, EN300-236023, and Z19756482, respectively; 
Kiev, Ukraine). CHEMBL1440472 (2- [(6- chloro- 3- 
nitro- 2-pyridinyl)amino]-3-methylbutanoic acid) was 
purchased from Key Organics (MS-1625; Bedford, 
MA). CHEMBL1621113 (N-[4-nitro-2-(trifluorome 
thyl)phenyl]propane-1,3-diamine) and CHEMBL107 
9062 ((Z)-4-[(4-nitrophenyl)amino]-4-oxobut-2-enoic 
acid) were purchased from ABCR GmbH (AB141160 
and AB414326, respectively; Karlsruhe, Germany).  
 
Analytical and spectroscopic characterization of 
oleacein mimetics  
 
NMR 
NMR spectra were recorded on an Agilent VNMRS-
400 (
1
H at 400.10 MHz). HPLC-MS. HPLC-MS were 
performed with a High-Performance Liquid 
Chromatography Thermo Ultimate 3000SD (Thermo 
Scientific Dionex) coupled to a photodiode array 
detector and a mass spectrometer LTQ XL ESI-ion trap 
(Thermo Scientific); 5μl of sample MeOH were injected 
(c=0.5mg/mL). Data from mass spectra were analyzed 
by electrospray ionization in positive and negative 
mode and peaks are given m/z (% of basis peak). The 
mobile phase used was a mixture of A = water + 0.05 
formic acid and B = Acetonitrile + 0.05 formic acid 
with method described as follows: flow 0.5 mL/min; 





Virtual profiling was performed with ligand- and 
structure-based software tools, using the chemical 
structure of oleacein as a seed, as described [54]. 
Briefly, the 3D virtual profiling tool compares a query 
molecule (i.e., oleacein) with the structures present in 
the Chembl(v19) reference database using 
Comparative Molecular Similarity Indices Analysis 
(CoMSIA) fields on a 3D grid. Molecules were 
compared according to their relationship with their 
environment using the 3D descriptors topologic 
surface area, lipophilicity, hydrogen bond donors/ 
acceptors count, and Van der Waals radii, among 
others, thereby obtaining biomimetic compounds with 
different structures.  
 
Docking and molecular dynamics calculations 
 
All docking, MD calculations and MM/GBSA rescoring 
were carried out as described [18, 22, 54].  
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Cell viability 
 
Cell viability was determined using a standard 
colorimetric MTT-based reduction assay 72 h after 





Mammosphere formation was monitored using 
Cell2Sphere™ assays (StemTek Therapeutics, Bilbao, 
Spain). Graded concentrations of oleacein mimetics 
were added to triplicate sets of wells on day 1 and the 
number of 6-day-old mammospheres was recorded as a 
measurement of CSC content. Images were recorded 
using a BioTek Cytation 5 image cytometer at 2.5× 
magnification. Prior to image acquisition, spheroid 
cultures were stained with a fluorescent vital dye to 
increase the accuracy of spheroid detection and 
analysis. The system was then set to count number, size, 
and aspect ratio of the objects. Thresholds were set to 
>100 µm in size and 0.4 as aspect ratio (with 1 being 
the aspect ratio of a perfect circle).  
 




 assay (StemCell Technologies, 
Vancouver, BC, Canada) was performed with or 
without the addition of hydroxytyrosol butyrate and (E)-
N-allyl-2-((5-nitrofuran-2-yl)methylene)hydrazinecarbo 
thioamide for 48 h.  
 
mTOR and DNMT activity/inhibition assays 
 
IC50 determinations for FRAP1 (mTOR) of oleacein 
mimetics were outsourced to Invitrogen (Life 
Technologies) using the FRET-based Z-LYTE™ 
SelectScreen Kinase Profiling Service. The effect of 
oleacein mimetics on the enzymatic activities of the 
recombinant human DNMT3A was outsourced to 
Reaction Biology Corp. (Malvern, PA) using 
HotSpot
SM
, a nanoliter-scale radioisotope filter binding 




All statistical analyses were performed using 
GraphPad Prism software (San Diego, CA). Data are 
presented as mean ± S.D. Comparisons of means of ≥ 
3 groups were performed by analysis of variance 
(ANOVA) and the existence of individual differences, 
in case of significant F values at ANOVA, were 
assessed by multiple contrasts. P values < 0.05 and 
<0.005 were considered to be statistically significant 
(denoted as
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Supplementary Figure 2. Top panels. MTT reduction-based measurement of cell viability is expressed as percentage uptake 
(OD570) relative to untreated controls (=100% cell viability). Bottom panels. Representative microscope images (×2.5 magnification) of 
mammospheres formed by MDA-MB-436 cells growing in sphere medium for 6 days in the absence or presence of graded concentrations of 
CHEMBL1085246. The number of mammospheres (>100 µm diameter) is expressed as means (columns) ± SD (bars). *P < 0.05 and **P < 
0.005, statistically significant differences from the untreated (control) group. 
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Supplementary Tables 
 
Please browse Full Text version to see the data of Supplementary Tables 6 and 7. 
 
Supplementary Table 1. Docking binding energies and MM/GBSA-based energy rescoring calculations of oleacein 






Target / PDBID 
Crystallographic cavity -7.1/-7.1 -26.8226 mTOR / 4JT6 
Cavity1 -7.3/-6.9 -17.155 mTOR / 4JT6 
Cavity4  -7.6/-7.8 -36.9931 mTOR / 4JT6 
Cavity8 -7.4/-7.3 -21.8981 mTOR / 4JT6 
Crystallographic cavity -7.9/-7.6 -30.567 DNMT / 4WXX 
Cavity1 -7.7/-7.7 -25.2792 DNMT / 4WXX 
Cavity2 -7.2/-7.2 -36.5163 DNMT / 4WXX 




Graphical representation of parental oleacein bound to several cavities of mTOR (4JT6, left) and DNMT (4WXX, right). 
Oleacein is colored in gold. In the case of mTOR, oleacein poses at cavities 1, 4, and 8, colored in blue, red, and yellow, 
respectively. In the case of DNMT, oleacein poses at cavities 1, 2, and 3, colored in blue, red, and yellow, respectively.  
 
 
Supplementary Table 2. Docking binding energies of oleacein mimetics against the crystallographic cavities of mTOR 
and DNMT.  
Oleacein mimetic Target/ PDBID 
ΔG kcal/mol 
R0 / R1 
Target / PDBID 
ΔG kcal/mol 
R0 / R1 
CHEMBL2172394 mTOR / 4JT6 -6.6 / -6.9 DNMT / 4WXX -6.9 / -7.1 
CHEMBL1085246 mTOR / 4JT6 -6.5 / -6.7 DNMT / 4WXX -7.6 / -7.5 
CHEMBL357073 mTOR / 4JT6 -7.3 / -7.2 DNMT / 4WXX -7.8 / -7.6 
CHEMBL1632504 mTOR / 4JT6 -5.9 / -6.0 DNMT / 4WXX -7.3 / -7.2 
CHEMBL126593 mTOR / 4JT6 -6.7 / -6.8 DNMT / 4WXX -6.8 / -6.8 
CHEMBL1950046 mTOR / 4JT6 -6.7 / -6.7 DNMT / 4WXX -6.7 / -6.7 
CHEMBL1440472 mTOR / 4JT6 -6.1 / -6.1 DNMT / 4WXX -7.0 / -7.0 
CHEMBL1300434 mTOR / 4JT6 -6.6 / -6.6 DNMT / 4WXX -7.5 / -7.5 
CHEMBL1890048 mTOR / 4JT6 -6.3 / -6.4 DNMT / 4WXX -6.8 / -6.8 
CHEMBL1180264 mTOR / 4JT6 -6.1 / -6.1 DNMT / 4WXX -7.3 / -7.4 
CHEMBL165714 mTOR / 4JT6 -6.3 / -6.3 DNMT / 4WXX -7.3 / -7.3 
CHEMBL1621113 mTOR / 4JT6 -6.7 / -6.6 DNMT / 4WXX -7.0 / -7.2 
 
www.aging-us.com 21074 AGING 
CHEMBL1079062 mTOR / 4JT6 -7.2 / -7.2 DNMT / 4WXX -7.7 / -7.7 
CHEMBL267516 mTOR / 4JT6 -6.6 / -6.7 DNMT / 4WXX -7.3 / -7.1 
CHEMBL154778 mTOR / 4JT6 -8.8 / -8.6 DNMT / 4WXX -8.1 / -8.1 
CHEMBL1366164 mTOR / 4JT6 -6.9 / -6.9 DNMT / 4WXX -7.4 / -7.4 
CHEMBL1642794 mTOR / 4JT6 -7.0/ -7.0 DNMT / 4WXX -7.6 / -7.6 
CHEMBL2165395 mTOR / 4JT6 -6.5 / -6.4 DNMT / 4WXX -7.3 / -7.3 
CHEMBL45196 mTOR / 4JT6 -7.1 / -6.6 DNMT / 4WXX -8.3 / -8.3 
CHEMBL2143987 mTOR / 4JT6 -6.2 / -6.2 DNMT / 4WXX -6.9 / -7.0 
Each calculation was performed twice (R0, R1) to avoid false positives. Differences less than 1 kcal/mol are negligible. 
 
Supplementary Table 3. Docking binding energies of oleacein mimetics against the best cavity of mTOR and DNMT 
shared with oleacein.  
Oleacein mimetic Cavity Target / PDBID 
ΔG 
kcal/mol 
R0 / R1 
Cavity Target / PDBID 
ΔG kcal/mol 
R0 / R1 
CHEMBL2172394 Cavity4 mTOR / 4JT6 -7.8 / -7.8 Cavity3 DNMT / 4WXX -7.3 / -7.4 
CHEMBL1085246 Cavity4 mTOR / 4JT6 -7.6 / -7.4 Cavity2 DNMT / 4WXX -7.0 / -7.0 
CHEMBL357073 Cavity4 mTOR / 4JT6 -7.7 / -7.6 Cavity2 DNMT / 4WXX -7.4 / -7.6 
CHEMBL1632504 Cavity8 mTOR / 4JT6 -6.8 / -6.7 Cavity2 DNMT / 4WXX -7.2 / -7.0 
CHEMBL126593 Cavity1 mTOR / 4JT6 -7.1 / -7.1 Cavity2 DNMT / 4WXX -6.7 / -6.8 
CHEMBL1950046 Cavity4 mTOR / 4JT6 -7.1 /-7.1 Cavity2 DNMT / 4WXX -6.8 / -6.8 
CHEMBL1440472 Cavity8 mTOR / 4JT6 -7.0 / -7.4 Cavity4 DNMT / 4WXX -7.0 / -7.0 
CHEMBL1300434 Cavity8 mTOR / 4JT6 -7.2 / -7.2 Cavity2 DNMT / 4WXX -7.7 / -7.8 
CHEMBL1890048 Cavity4 mTOR / 4JT6 -7.0 / -7.0 Cavity2 DNMT / 4WXX -6.9 / -6.8 
CHEMBL1180264 Cavity8 mTOR / 4JT6 -7.1 / -6.7 Cavity2 DNMT / 4WXX -7.3 / -7.4 
CHEMBL165714 Cavity8 mTOR / 4JT6 -7.2 / -7.4 Cavity1 DNMT / 4WXX -6.9 / -6.8 
CHEMBL1621113 Cavity1 mTOR / 4JT6 -7.0 / -6.5 Cavity2 DNMT / 4WXX -7.3 / -7.3 
CHEMBL1079062 Cavity8 mTOR / 4JT6 -7.3 / -7.5 Cavity2 DNMT / 4WXX -7.5 / -7.9 
CHEMBL267516 Cavity8 mTOR / 4JT6 -7.1 / -7.1 Cavity2 DNMT / 4WXX -7.2 / -7.1 
CHEMBL154778 Cavity4 mTOR / 4JT6 -8.1 / -8.2 Cavity2 DNMT / 4WXX -8.0 / -7.8 
CHEMBL1366164 Cavity4 mTOR / 4JT6 -7.2 / -7.4 Cavity2 DNMT / 4WXX -7.2 / -7.2 
CHEMBL1642794 Cavity1 mTOR / 4JT6 -7.8 / -7.6 Cavity2 DNMT / 4WXX -7.5 / -7.5 
CHEMBL2165395 Cavity8 mTOR / 4JT6 -7.6 / -7.6 Cavity2 DNMT / 4WXX -7.4 / -7.0 
CHEMBL45196 Cavity4 mTOR / 4JT6 -8.4 / -8.0 Cavity1 DNMT / 4WXX -8.3 / -8.1 
CHEMBL2143987 Cavity4 mTOR / 4JT6 -7.1 / -6.8 Cavity3 DNMT / 4WXX -6.9 / -7.0 
 
Each calculation was performed twice (R0, R1) to avoid false positives. Differences less than 1 kcal/mol are negligible. 
 
Supplementary Table 4. MM/GBSA-based binding energy rescoring calculations over MD simulations of 
computationally-predicted oleacein mimetics against the crystallographic cavities of mTOR and DNMT. 
Oleacein mimetic Target/ PDBID ΔG kcal/mol Target / PDBID ΔG kcal/mol 
CHEMBL2172394 mTOR / 4JT6 -18.4177 DNMT / 4WXX -11.8887 
CHEMBL1085246 mTOR / 4JT6 -27.4436 DNMT / 4WXX -17.8140 
CHEMBL357073 mTOR / 4JT6 -25.0102 DNMT / 4WXX -28.4676 
CHEMBL1632504 mTOR / 4JT6 -25.7896 DNMT / 4WXX -38.2609 
CHEMBL126593 mTOR / 4JT6 -29.2106 DNMT / 4WXX -25.7134 
CHEMBL1950046 mTOR / 4JT6 -20.2999 DNMT / 4WXX -24.3167 
CHEMBL1440472 mTOR / 4JT6 -16.6468 DNMT / 4WXX -27.5899 
CHEMBL1300434 mTOR / 4JT6 -38.7014 DNMT / 4WXX -33.3421 
CHEMBL1890048 mTOR / 4JT6 -19.6392 DNMT / 4WXX -26.0912 
CHEMBL1180264 mTOR / 4JT6 -18.2272 DNMT / 4WXX -31.7196 
CHEMBL165714 mTOR / 4JT6 -16.1321 DNMT / 4WXX -12.1247 
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CHEMBL1621113 mTOR / 4JT6 -22.9663 DNMT / 4WXX -26.6488 
CHEMBL1079062 mTOR / 4JT6 -17.4413 DNMT / 4WXX -24.2025 
CHEMBL267516 mTOR / 4JT6 -27.371 DNMT / 4WXX -32.8788 
CHEMBL154778 mTOR / 4JT6 -30.5493 DNMT / 4WXX -21.6215 
CHEMBL1366164 mTOR / 4JT6 -24.3303 DNMT / 4WXX -15.4957 
CHEMBL1642794 mTOR / 4JT6 -24.1435 DNMT / 4WXX -16.1264 
CHEMBL2165395 mTOR / 4JT6 -19.8235 DNMT / 4WXX -33.4134 
CHEMBL45196 mTOR / 4JT6 -27.2624 DNMT / 4WXX -24.5175 
CHEMBL2143987 mTOR / 4JT6 -32.407 DNMT / 4WXX -36.4821 
 
Supplementary Table 5. MM/GBSA-based binding energy rescoring calculations over MD simulations of 
computationally-predicted oleacein mimetics against against the best cavity of mTOR and DNMT shared with 
oleacein. 
Oleacein candidate Cavity Target / PDBID ΔG kcal/mol Cavity Target / PDBID ΔG kcal/mol 
CHEMBL2172394 Cavity4 mTOR / 4JT6 -34.392 Cavity3 DNMT / 4WXX -31.0757 
CHEMBL1085246 Cavity4 mTOR / 4JT6 -19.6725 Cavity2 DNMT / 4WXX -36.9931 
CHEMBL357073 Cavity4 mTOR / 4JT6 -33.5462 Cavity2 DNMT / 4WXX -34.3628 
CHEMBL1632504 Cavity8 mTOR / 4JT6 -24.6272 Cavity2 DNMT / 4WXX -36.6319 
CHEMBL126593 Cavity1 mTOR / 4JT6 -26.6329 Cavity2 DNMT / 4WXX -35.3592 
CHEMBL1950046 Cavity4 mTOR / 4JT6 -31.6794 Cavity2 DNMT / 4WXX -21.7283 
CHEMBL1440472 Cavity8 mTOR / 4JT6 -21.2853 Cavity4 DNMT / 4WXX -29.360 
CHEMBL1300434 Cavity8 mTOR / 4JT6 -27.361 Cavity2 DNMT / 4WXX -33.9773 
CHEMBL1890048 Cavity4 mTOR / 4JT6 -21.2089 Cavity2 DNMT / 4WXX -26.2952 
CHEMBL1180264 Cavity8 mTOR / 4JT6 -29.4140 Cavity2 DNMT / 4WXX -32.3981 
CHEMBL165714 Cavity8 mTOR / 4JT6 -21.4634 Cavity1 DNMT / 4WXX -30.3770 
CHEMBL1621113 Cavity1 mTOR / 4JT6 -21.0309 Cavity2 DNMT / 4WXX -29.3269 
CHEMBL1079062 Cavity8 mTOR / 4JT6 -24.7585 Cavity2 DNMT / 4WXX -24.4205 
CHEMBL267516 Cavity8 mTOR / 4JT6 -44.6454 Cavity2 DNMT / 4WXX -28.1508 
CHEMBL154778 Cavity4 mTOR / 4JT6 -25.0387 Cavity2 DNMT / 4WXX -22.9832 
CHEMBL1366164 Cavity4 mTOR / 4JT6 -17.8085 Cavity2 DNMT / 4WXX -19.6201 
CHEMBL1642794 Cavity1 mTOR / 4JT6 -19.439 Cavity2 DNMT / 4WXX -20.6555 
CHEMBL2165395 Cavity8 mTOR / 4JT6 -27.2639 Cavity2 DNMT / 4WXX -25.8227 
CHEMBL45196 Cavity4 mTOR / 4JT6 -17,1961 Cavity1 DNMT / 4WXX -32,1555 
CHEMBL2143987 Cavity4 mTOR / 4JT6 -40.3344 Cavity3 DNMT / 4WXX -43.6863 
 
Supplementary Table 6. Key interacting residues of oleacein mimetics to the catalytic site of mTOR. Interactions 
other than electrostatic are highlighted in yellow (possible) or green (reliable).  
 
Supplementary Table 7. Key interacting residues of oleacein mimetics to the catalytic site of DNMT. Interactions 
other than electrostatic are highlighted in yellow (possible) or green (reliable).  
 
 
 
 
